Low-dose olanzapine approach ‘new standard of care’ for chemotherapy nausea and vomiting
Low-dose olanzapine significantly protects against nausea and vomiting compared with placebo for women with breast cancer receiving anthracycline plus cyclophosphamide chemotherapy, show phase 3 trial findings published in The Lancet Oncology.
